EBITDA Margin % is calculated as EBITDA divided by its Revenue. Janux Therapeutics's EBITDA for the
three
months ended in Mar. 2026 was $-33.74 Mil. Janux Therapeutics's Revenue for the
three
months ended in Mar. 2026 was $3.73 Mil. Therefore, Janux Therapeutics's EBITDA margin for the quarter that ended in Mar. 2026 was -903.94%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Janux Therapeutics EBITDA Margin % Related Terms
Janux Therapeutics EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Janux Therapeutics's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JANX vs ANNX, XNCR, SPRY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Janux Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Janux Therapeutics EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Janux Therapeutics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Janux Therapeutics's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Janux Therapeutics (JANX) has a EBITDA Margin % of -903.94% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Janux Therapeutics and its competitors. According to the industry distribution chart, Janux Therapeutics ranks #760 out of 945 companies in the Biotechnology industry, placing it in the top 80.4%.
Is Janux Therapeutics' EBITDA Margin % too high?
Janux Therapeutics' current EBITDA Margin % is -903.94%. Based on the distribution chart, Janux Therapeutics ranks #760 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Janux Therapeutics has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Janux Therapeutics' EBITDA Margin % compare to ANNX and XNCR?
According to the Biotechnology industry distribution chart, Janux Therapeutics ranks #760 out of 945 companies for EBITDA Margin %. This places Janux Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Janux Therapeutics and its competitors. Janux Therapeutics's current EBITDA Margin % is -903.94%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Janux Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Janux Therapeutics (JANX) is currently considered Possible Value Trap. The stock's GF Value™ is $39.21, compared to a current price of $15.22 — trading 61.2% below its estimated fair value. The current EBITDA Margin % is -903.94%. Janux Therapeutics' overall GF Score™ is 46/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Janux Therapeutics (JANX), the current EBITDA Margin % is -903.94% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Janux Therapeutics (JANX) Overvalued in 2026?
Based on GuruFocus' analysis, Janux Therapeutics stock appears to be undervalued.
The current stock price of $15.22 is trading 61.2% below its estimated GF Value™ of $39.21.
GuruFocus considers Janux Therapeutics to be Possible Value Trap.
Key valuation signals for JANX:
EBITDA Margin %: -903.94%
GF Value™: $39.21 vs. price of $15.22 (61.2% below fair value)
No single metric tells the full story. See the JANX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
46GF Score
Get the complete analysis for JANX
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JANX has been successfully added to your 
